Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

ABSTRACT: PURPOSE:The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association between chemotherapy intensity and survival in advanced NSCLC. METHODS:This retrospective cohort study included adults with advanced lung cancer who received first-line myelosuppressive platinum-based chemotherapy (January 2007-December 2010) in ~?230 US Oncology Network community practices. Dose delays ??7 days, dose reductions ??15%, and RDI relative to standard regimens were described. Overall survival (OS) was measured using Kaplan-Meier and Cox proportional hazard (PH) models. RESULTS:Among 3866 patients with advanced NSCLC, 32.4% experienced dose delays ??7 days, 50.1% experienced dose reductions ??15%, and 40.4% had RDI

SUBMITTER: Crawford J 

PROVIDER: S-EPMC6954126 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature